These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21280089)

  • 1. Gait alterations in healthy carriers of the LRRK2 G2019S mutation.
    Mirelman A; Gurevich T; Giladi N; Bar-Shira A; Orr-Urtreger A; Hausdorff JM
    Ann Neurol; 2011 Jan; 69(1):193-7. PubMed ID: 21280089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
    Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
    Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
    Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
    Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
    Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
    Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
    Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease.
    Sánchez-Rodríguez A; Tirnauca C; Salas-Gómez D; Fernández-Gorgojo M; Martínez-Rodríguez I; Sierra M; González-Aramburu I; Stan D; Gutierrez-González A; Meissner JM; Andrés-Pacheco J; Rivera-Sánchez M; Sánchez-Peláez MV; Sánchez-Juan P; Infante J
    Parkinsonism Relat Disord; 2022 May; 98():21-26. PubMed ID: 35421781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arm swing as a potential new prodromal marker of Parkinson's disease.
    Mirelman A; Bernad-Elazari H; Thaler A; Giladi-Yacobi E; Gurevich T; Gana-Weisz M; Saunders-Pullman R; Raymond D; Doan N; Bressman SB; Marder KS; Alcalay RN; Rao AK; Berg D; Brockmann K; Aasly J; Waro BJ; Tolosa E; Vilas D; Pont-Sunyer C; Orr-Urtreger A; Hausdorff JM; Giladi N
    Mov Disord; 2016 Oct; 31(10):1527-1534. PubMed ID: 27430880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease.
    Hashad DI; Abou-Zeid AA; Achmawy GA; Allah HM; Saad MA
    Genet Test Mol Biomarkers; 2011 Dec; 15(12):861-6. PubMed ID: 21699405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
    Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
    Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclinical signs in LRRK2 mutation carriers.
    Johansen KK; White LR; Farrer MJ; Aasly JO
    Parkinsonism Relat Disord; 2011 Aug; 17(7):528-32. PubMed ID: 21641848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.
    Alcalay RN; Mejia-Santana H; Tang MX; Rosado L; Verbitsky M; Kisselev S; Ross BM; Louis ED; Comella CL; Colcher A; Jennings D; Nance MA; Bressman S; Scott WK; Tanner C; Mickel SF; Andrews HF; Waters CH; Fahn S; Cote LJ; Frucht SJ; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Marsh L; Hiner B; Siderowf A; Caccappolo E; Ottman R; Clark LN; Marder KS
    Arch Neurol; 2009 Dec; 66(12):1517-22. PubMed ID: 20008657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
    Inzelberg R; Cohen OS; Aharon-Peretz J; Schlesinger I; Gershoni-Baruch R; Djaldetti R; Nitsan Z; Ephraty L; Tunkel O; Kozlova E; Inzelberg L; Kaplan N; Fixler Mehr T; Mory A; Dagan E; Schechtman E; Friedman E; Hassin-Baer S
    Neurology; 2012 Mar; 78(11):781-6. PubMed ID: 22323743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.
    Thaler A; Helmich RC; Or-Borichev A; van Nuenen BF; Shapira-Lichter I; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T; Mirelman A;
    Eur J Neurosci; 2016 Jan; 43(1):106-12. PubMed ID: 26536050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2015 Feb; 36(2):1105-9. PubMed ID: 25475535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.